Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA. Dark GG, et al. Among authors: jayson g. J Clin Oncol. 2005 Mar 20;23(9):1859-66. doi: 10.1200/JCO.2005.02.028. Epub 2005 Feb 7. J Clin Oncol. 2005. PMID: 15699482 Clinical Trial.
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G. Ledermann JA, et al. Among authors: jayson g. J Clin Oncol. 2011 Oct 1;29(28):3798-804. doi: 10.1200/JCO.2010.33.5208. Epub 2011 Aug 22. J Clin Oncol. 2011. PMID: 21859991 Clinical Trial.
PARP inhibitors in BRCA mutation-associated ovarian cancer.
Clamp A, Jayson G. Clamp A, et al. Among authors: jayson g. Lancet Oncol. 2015 Jan;16(1):10-2. doi: 10.1016/S1470-2045(14)71172-6. Epub 2014 Dec 4. Lancet Oncol. 2015. PMID: 25481790 No abstract available.
VEGF inhibitors and advanced ovarian cancer.
Jayson G. Jayson G. Lancet Oncol. 2011 Nov;12(12):1082-3. doi: 10.1016/S1470-2045(11)70269-8. Epub 2011 Oct 10. Lancet Oncol. 2011. PMID: 21992854 No abstract available.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Drew Y, et al. Among authors: jayson g. Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22. Br J Cancer. 2016. PMID: 27002934 Free PMC article. Clinical Trial.
Psychosexual morbidity in women with ovarian cancer.
Logue CA, Pugh J, Jayson G. Logue CA, et al. Among authors: jayson g. Int J Gynecol Cancer. 2020 Dec;30(12):1983-1989. doi: 10.1136/ijgc-2020-002001. Epub 2020 Oct 28. Int J Gynecol Cancer. 2020. PMID: 33115791 Free PMC article. Review.
New therapeutic agents in ovarian cancer.
Collinson F, Jayson G. Collinson F, et al. Among authors: jayson g. Curr Opin Obstet Gynecol. 2009 Feb;21(1):44-53. doi: 10.1097/GCO.0b013e32831ffe71. Curr Opin Obstet Gynecol. 2009. PMID: 19125003 Review.
234 results